Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
ERS Genomics Limited
organization2 mentionslast seen Oct 22, 2026
CRISPR licensing company providing access to foundational CRISPR/Cas9 intellectual property.
Relationships 5
- ERS Genomics LimitedemploysJohn E. Milad99% confidence2 sources
- ERS Genomics LimitedownsCVC Patents98% confidence2 sources
- ERS Genomics Limitedpartners withKU Leuven95% confidence1 source
- ERS Genomics Limitedpartners withSai Life Sciences Limited92% confidence1 source
- ERS Genomics LimitedcommercializesCRISPR/Cas990% confidence1 source
Relationship
ERS Genomics LimitedemploysJohn E. Milad
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- newsPR NewswireOct 22, 2026ERS Genomics and KU Leuven Sign CRISPR/Cas9 License Agreement to Expand CRISPR-Enabled Research Services
John E. Milad, Chief Executive Officer, ERS Genomics
- newsPR NewswireSep 22, 2026ERS Genomics and Sai Life Sciences Sign CRISPR/Cas9 License Agreement to Advance Precision Genome Editing in Drug Discovery and Development
John E. Milad, Chief Executive Officer, ERS Genomics